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Assessment of Thyroid Function in Pregnant Women From Rimal 
Health Center ,Gaza City. 
Abstract 
Background. Pregnancy is associated with significant but reversible changes in 
thyroid function tests results, which are as a result of a normal physiologic state. 
Pregnancy influences thyroid function and may bring to light mild and latent 
disorders. This study focused on thyroid hormones as the human fetal thyroid does not 
secrete thyroid hormones until approximately 12 weeks of gestation, the fetus is 
dependent until that time on a supply from the maternal circulation. Thyroid 
dysfunction has been related to obstetrical complications such as premature delivery, 
gestational hypertension, preeclampsia, and placental abruption.  
Objective: to assess the maternal thyroid function in the first trimester of pregnant  
women from Rimal health center-Gaza city. 
Materials and methods.  A cross sectional study was designed with 90  normal 
pregnant women who were randomly selected from the first trimesters attending 
Rimal Health Center and  80 randomly selected  non-pregnant healthy female 
controls.  Age range in both groups was 18-40 years.  Thyroid function tests were 
carried out by measuring serum levels of thyroid stimulating hormone (TSH), free 
thyroxin (FT4), and free triiodothyronine (FT3). They were measured using 
Microparticles Enzyme Immunoassay   (MEIA). SPSS was used to analyse obtained 
data. 
 Results: The results showed that  there was a significant increased between the non 
pregnant women group and pregnant women for FT4 and FT3 where the p-value is 
0.04 and 0.030 respectively. the mean TSH levels of pregnant women was lower than 
the mean level of non pregnant but did not show significant difference in first  
trimester compared with non-pregnant women. Also there was a significant statistical 
difference between the groups of different age for FT4 and FT3 where the p- value 
was 0.034 and 0.038 among  the non pregnant women group. On the other hand, there 
was no statistically significant relationship between thyroid function in pregnancy and 
family history of thyroid problems, genetic disease, and hypertension among women 
in the study sample. 
 





  غزه  ة مدين فيالنساء الحوامل من مركز الرمال الصحي لدى الدرقيةتقيم وظائف الغدة 
 الغدة الدرقيـة في  حدثي  ما من التغيرات الفسيولوجية بما في ذلك ثناء فتره الحمل لعدد أ  في تعرض المرأة ت 
النمـو الطبيعـي لمـخ   كما أن األهمية من ا الغدة الدرقية لما له ات هرمون  على تركيز ال هذه الدراسة وهدفت 
ن يعوق النمو العصبي أ أو الكثير يمكن ان القليل منه  وأل ، الغدة الدرقية اتالجنين يخضع إلمداد منتظم لهرمون 
ارتفـاع ، دة المبكـرة   الوال:ث مضاعفات الوالدة مثلدو  ولكن الخلل في الغدة الدرقية يؤدي إلى ح ، للجنين
 التغيرات في اختبـارات وظـائف وقد أجريت الدراسة لمعرفه. انفكاك المشيمة، تسمم الحمل ، ضغط الحمل 
  . النساء الحوامل لدى األولى الثالثةالغدة الدرقية خالل الشهور
       ف ي مدین ھ الحمل األولى من  الشهور الثالثة النساء الحوامل في لدىيم وظائف الغدة الدرقية يتق : الهـدف 
  .ةغز
 سيده 90من   مكونه األولى ةلمجموعا: مجموعتين إلىومقسمه  ،ة سيد 170  من  تم دراسة عينه مكونه : الطرق
  كل من  وقد تم فحص ، حامل  غير ة سيد ) 80( مكونه من الثانية والمجموعة من الحمل األولى الفترةحامل في 
   .TSH,FT4 and FT3 هرمون
كـل مـن ل الدرقية الغدةووظائف ،ما بين الحمل " إحصائية"الدراسة وجود عالقة ذات دالله أظهرت  : النتائج
وكان هنـاك  ، الحوامللسيدات غيربين السيدات الحوامل وا   ثايرونين   وهرمون ثالثي ، الثيروكسين يهرمون
 النتائج وجـود هرت أظ كما إحصائية، ولكن لم يكن ذا دالله  أيضا يةهرمون المحفز للغده الدرق الفرق ما بين 
  أظهرت كذلك ،حواملالالسيدات غير  ة لدى  الدرقي ة ووظائف الغد دة بين عمر السي ةحصائيإ ذات دالله ة عالق
ـ ، الدم ،طغض( بين كل من ةحصائيإ ذات دالله ة عدم وجود عالق إلىالنتائج   ةتـاريخ المـرض فـي العائل
   .حجم عينه البحث على مستوى ة الدرقيةظائف الغدومع ) ةمراض الوراثياأل،
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Pregnancy is associated with significant but reversible changes in thyroid function  
which are a result of normal physiologic state and hormonal changes that alter thyroid 
function (1).  These changes mean that laboratory tests of thyroid function must be 
interpreted with caution during pregnancy (2). 
  
Thyroid function change during pregnancy due to the influence of two main 
hormones (a) human chorionic gonadotropin (hCG), the hormone that is measured in 
the pregnancy test. Human chorionic gonadotropin can weakly turn on the thyroid and 
the high circulating hCG levels in the first trimester may result in a slightly low 
thyroid stimulating hormone (TSH) in the first trimester and then return to normal 
throughout the duration of pregnancy (1). TSH suppression is a transient phenomenon 
and TSH concentrations generally remain within non pregnant reference intervals in 
normal pregnancy (3). (b) estrogen, the main female hormone, estrogen stimulates 
thyroid binding globulin (TBG) formation and increases its half life, with maximal 
TBG levels around 20 weeks, leading to increases in serum thyroxine levels (4).  
Estrogen increases the amount of thyroid hormone binding proteins in the serum 
which increases the total thyroid hormone levels in the blood since >99% of the 
thyroid hormones in the blood are bound to these proteins (5). 
 
However, measurements of “Free” hormone (that is not bound to protein, 
representing the active form of the hormone) usually remain normal (6). The thyroid 
is functioning normally if the TSH, free thyroxine (T4) and free triiodothyronine (T3 ) 
are all normal throughout pregnancy. Therefore, thyroid function is frequently 
assessed during pregnancy, both to evaluate suspected thyroid abnormalities, and to 
monitor the status of pre-existing thyroid disease (7). As thyroid disorders are the 
most common endocrinology disorders of childbearing age (8). Moreover, thyroid 
disorders may affect both the pregnant woman and the developing fetus; where 
thyroid hormones having important role in embryogenesis and fetal development (9). 
The fetus is completely dependent on the mother for thyroid hormone (10). 
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  Thyroid disorders such as chronic thyroiditis, hypothyroidism, Graves' disease,     
etc. are relatively common in pregnant women (11).  Disorders of the thyroid include 
both overt and mild/subclinical hypothyroidism and hyperthyroidism and goitre. 
Hypothyroidism is estimated to occur in 0.3-0.5% of pregnancies (12) Subclinical 
hypothyroidism appears to occur in 2-3% (13) .Hyperthyroidism during gestation, 
usually caused by Graves disease, is rare (0.2%). (14) 
 
Uncontrolled hyperthyroidism and hypothyroidism  are associated with serious 
maternal, fetal, and neonatal morbidity, and mortality. Maternal complications include 
miscarriage, pregnancy-induced hypertension, preterm labor, placental abruption, 
heart failure, and thyroid storm. Fetal and neonatal complications include stillbirth, 
low birth weight, goiter, hyperthyroidism, and hypothyroidism (15,16,17). 
 
1.2  Problem statement 
Checking routinely (screening) for possible thyroid problems was not considered 
important in pregnant women, where pregnant women with thyroid disease do not 
always develop symptoms, and when they do, these symptoms can sometimes be 
attributed to the pregnancy itself. It is only considered important when pregnant 
women  had the typical symptoms of hypothyroidism or hyperthyroidism. Lack of 
early diagnosis increase the risk of pre-term birth, placental abruption, fetal death, and 
impaired neurological development in the child. For these reasons, it is important to 
ensure optimal maternal thyroid function during pregnancy so accurate laboratory 
assessment of maternal thyroid function is important. Moreover, for  Gaza city  
thyroid function in pregnant women have not been carried before. 
 
1.3   Objectives     
The general objective of this study is to assess the maternal thyroid function in the 




The specific objectives of the study are: 
1- To determine thyroid  hormone levels in the first trimester of 
pregnancy. 
2- To observe any changes in thyroid hormone levels. 
3- To study possible relation  between family history of thyroid problem, 
genetic disease, hypertension and age.   
1.4   Significance  
This research will be conducted for the first time in Gaza city. According to 
preliminary  statistics obtained from a group of obstetric & gynecology physicians 
(ob|Gyn), many pregnant women suffer thyroid dysfunction. The assessment of 
thyroid function in pregnant women will draw the attention of (ob|Gyn) physicians to 

























2.1 The critical role of the thyroid gland  
The thyroid gland plays a vital role in the overall body function during all stages 
of life. Although relatively small, it produces hormones that regulate the body's 
overall metabolism, the rate at which the body produces energy from nutrients. 
Thyroid hormones influence growth and development, oxygen consumption and heat  
production, nerve function, and metabolism of lipids, carbohydrates, proteins, nucleic 
acids, vitamins, and inorganic ions. They also have important effects on other 
hormone actions (18).  
 
If left untreated, thyroid disease can lead to an increased risk of heart disease, 
osteoporosis and infertility. An estimated 13 million Americans have a thyroid 
problem, but more than half remain undiagnosed.  Thyroid hormones are particularly 
important during pregnancy and play a key role in fetal development. Until the fetal 
thyroid gland is developed at approximately 12 week's of gestation, the maternal 
thyroid is solely responsible for delivering thyroid hormone, which is essential to fetal 
brain development. The placenta and amniotic fluid transfer small but crucial amounts 
of thyroid hormone from the mother to the fetus.(19)  
 
2.2  Thyroid gland 
2.2.1 Anatomy of the thyroid gland 
`The thyroid gland is one of the largest endocrine glands in the body, weighing 
2-3 grams in neonates and 18-60 grams in adults, and is increased in pregnancy. This 
gland is found in the neck inferior to the thyroid cartilage (also known as the Adam's 
apple in men) as shown in Figure (2.1). It is a butterfly-shaped organ and composed 
of two cone- like lobes: right lobe and left lobe, connected with the isthmus. The 
organ is situated on the anterior side of the neck, lying against and around the larynx 



















Figure 2.1: Thyroid gland (21) 
 
2.2.2 Physiology of thyroid gland 
Thyroid  gland produces the hormones T4, T3, and calcitonin . Up to 80% of the 
T4 is converted to T3 by peripheral organs such as the liver, kidney and spleen. T3 is 
about ten times more active than T4 (22). 
 
2.3  The thyroid hormones 
The thyroid gland secretes two hormones, L-T4 and L - T3. The thyroid hormones are 
the only iodine-containing compounds with established physiologic significance in 
vertebrates (23). T4 is the predominant form of thyroid hormone. It’s called T4 
because it contains four iodine atoms for each hormone molecule. When one specific 
iodine atom is removed from the T4 molecule, it becomes RT3 or T3, the form 
necessary for doing the thyroid’s job for the body’s cells. Nearly all cells have special 
enzymes inside of them (deiodinases) that remove an iodine from T4 to make it into 
T3.  The thyroid gland usually releases around 80 percent of its hormones as T4 and 
20 percent as T3 (24). When this T4 and T3 enter the blood, most of these hormones 
stick to blood proteins made by the liver, called thyroid hormone transport proteins. 
Thyroid hormones (TH) are transported in serum non covalently bound to three 
proteins: T4- (TBG), albumin, and transthyretin previously called pre- albumin (25). 
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The relative distribution of TH among the binding proteins is directly related to both 
their affinities and concentrations. In steady state conditions, the bound hormone 
fraction is in equilibrium with a free unbound fraction, which represents a minute 
amount of the total circulating TH: 0.03% for T4 and 0.3% for T3 (26). The 
production of thyroid hormones is based on the organization of thyroid epithelial cells 
in functional units, the thyroid follicles, a single layer of polarized forms envelope of 
a spherical structure with an internal compartment, the follicle lumen. Thyroid 
hormone synthesis is dependent on the cell polarity that conditions the targeting of 
specific membrane protein, either on the external side of the follicle (facing the blood 
capillaries) or on the internal side and on the tightness of the follicle lumen that 
allows the gathering of substrates and the storage of products of the reactions. Thyroid 
hormone secretion relies on the existence of stores of pre-synthesized hormones in the 
follicle lumen and cell polarity-dependent transport and handling processes leading to 
the delivery of hormones into the blood stream(23). After concentrating iodide, the 
thyroid rapidly oxidizes it and binds it to tyrosyl residues in thyroglobulin (TG) 
followed by coupling of iodotyrosines to form T4 and T3. The process requires the 
presence of iodide, a peroxidase (TPO), a supply of H2O2, and an iodine acceptor 
protein (TG) (27). 
 
2.3.1 Thyroxine  
3,5,3',5'-tetraiodothyronine (T4), a form of thyroid hormones, is the major 
hormone secreted by the follicular cells of the thyroid gland. Thyroxine is 
synthesized via the iodination and covalent bonding of the phenyl portions of 
tyrosine residues found in an initial peptide, TG  which is secreted into thyroid 
granules. These iodinated diphenyl compounds are cleaved from their peptide 
backbone upon being stimulated by thyroid stimulating hormone. T4 is 
transported in blood, with globulin (TBG), 99.95% of the secreted T4 being 
protein bound principally to thyroxine-binding globulin, to transthyretin and 
serum albumin.  T4 is involved in controlling the rate of metabolic processes in 
the body and influencing physical development. Thyroxine is a prohormone and a 
reservoir for the active thyroid hormone T3 which is about four times more potent. 
T4 is converted in the tissues by deiodinases to T3. The "D" isomer is called 
"Dextrothyroxine and is used as a lipid modifying agent. The half-life of thyroxine 




2.3.2 Triiodothyronine  
TSH activates the production of T4 and T3. This process is under regulation. 
In the thyroid, T4 is converted to T3. TSH is inhibited mainly by T3. The thyroid 
gland releases greater amounts of T4 than T3, so plasma concentrations of T4 are 40-
fold higher than those of T3. Most of the circulating T3 is formed peripherally by 
deiodination of T4 (85%), a process that involves the removal of iodine from carbon 5 
on the outer ring of T4. Thus, T4 acts as prohormone for T3. In addition, T3 exhibits 
greater activity and is produced in smaller quantity. It is the most powerful thyroid 
hormone, and affects almost every process in the body, including body temperature, 
growth, and heart rate. The biological half-life is 2.5 days (28). 
 
2.3.3 Calcitonin 
An additional hormone produced by the thyroid gland contributes to the regulation 
of blood calcium levels. Parafollicular cells produce calcitonin in response to 
hypercalcemia. Calcitonin stimulates movement of calcium into bone, in opposition to 
the effects of parathyroid hormone (PTH). However, calcitonin seems far less 
essential than PTH, as calcium metabolism remains clinically normal after removal of 
the thyroid, but not the parathyroids (29). 
 
2.4 Synthesis of thyroid hormones 
The first step in the formation of thyroid hormones (TH) involves the active 
accumulation of iodide from the extracellular fluid across the basolateral membrane 
and into the thyroid follicular cell. The protein responsible for this was previously 
described as the iodide trap or iodide pump. Because the transport into the follicular 
cell of iodide against its concentration gradient is coupled with transport of sodium, 
the protein was named the sodium/iodide symporter (NIS) (30).  The iodide pump is 
linked to a Na+-K+-pump, which requires energy in the form of oxidative 
phosphorylation (ATP) and is inhibited by ouabain. The thyroid absorption of iodide 
is also inhibited by negative ions (such as perchlorate, pertechnetate, thiocyanate and 
nitrate), because they compete with the iodide at the trap. In the follicular cell, iodide 
passes down its electrochemical gradient through the apical membrane and into the 
follicular colloid. Iodide is instantly oxidised – with hydrogen peroxide as oxidant - 
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by a thyroid peroxidase to atomic or molecular iodine at the colloid surface of the 
apical membrane. Thiouracil and sulfonamides block this peroxidase. The rough 
endoplasmic reticulum synthesises a large storage molecule called thyroglobulin. This 
compound is build up by a long peptide chain with tyrosine units and a carbohydrate 
unit completed by the Golgi apparatus. Iodide-free thyroglobulin is transported in 
vesicles to the apical membrane, where they fuse with the membrane and finally 
release thyroglobulin at the apical membrane.  
 
At the apical membrane the oxidised iodide is attached to the tyrosine units (L-
tyrosine) in thyroglobulin at one or two positions, forming the hormone precursors 
mono-iodotyrosine (MIT), and di-iodotyrosine (DIT), respectively (Figure 2.2).   This 
and the following reactions are dependent on thyroid peroxidase in the presence of 
hydrogen peroxide -both located at the apical membrane. As MIT couples to DIT it 
produces tri-iodothyronine (3,5,3`-T3), whereas two DIT molecules form tetra-
iodothyronine (T4), or thyroxine. These two molecules are the two thyroid hormones. 




Figure 2.2: Structural formula of thyroid hormones and precursor 
compounds (23). 
The newly formed iodothyroglobulin forms one of the most important constituents 
of the colloid material, present in the follicle of the thyroid unit.  The other synthetic 
reaction, that is closely linked to organification, is a coupling reaction, where 
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iodotyrosine molecules are coupled together.  If two di-iodotyrosine molecules couple 
together, the result is the formation of thyroxin (T4).  If a di-iodotyrosine and a mono-
iodotyrosine are coupled together, the result is the formation of tri-iodothyronine 
(T3). (Figure 2.3). 
 
Figure 2.3: Synthesis of thyroid hormones 
 
Iodide is organified in the tyrosyl residues of Tg in a reaction catalyzed by TPO, in 
the presence of H2O2, Tg contains MIT, DIT, T3, and T4 and is stored in colloid until 
T3 and T4 need to be released into the blood (32). 
 
From the perspective of the formation of thyroid hormone, the major coupling 
reaction is the di-iodotyrosine coupling to produce T4.  Although T3 is more 
biologically active than T4, the major production of T3 actually occurs outside of the 
thyroid gland.  The majority of T3 is produced by peripheral conversion from T4 in a 
deiodination reaction involving a specific enzyme which removes one iodine from the 
outer ring of T4.  The T3 and T4 released from the thyroid by proteolysis reach the 
bloodstream where they are bound to thyroid hormone binding proteins. The major 
thyroid hormone binding protein is thyroxin binding globulin (TBG) which accounts 
for about 75% of the bound hormone. In order to attain normal levels of thyroid 
hormone synthesis, an adequate supply of iodine is essential. The recommended 
minimum intake of iodine is 150 micrograms a day.  Intake of less than 50 
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micrograms a day is associated with goiter. High iodine levels inhibit iodide oxidation 
and organification.  Additionally, iodine excess inhibits thyroglobulin proteolysis 
(33).  
 
Cells of the brain are a major target for the thyroid hormones T3 and T4. Thyroid 
hormones play a particularly crucial role in brain maturation during fetal 
development. A transport protein called organic anion transporter (OATP1C1) has 
been identified that seems to be important for T4 transport across the blood brain 
barrier. A second transport protein called monocarboxylate transporter 8 (MCT8) is 
important for T3 transport across brain cell membranes (34). 
 
2.5 Mechanisms of thyroid hormone action 
 
As illustrated in Figure 2.4.   circulating free TH enters the cell by either passive 
diffusion or other. TH then enters the nucleus, where it binds to the nuclear thyroid-
hormone receptor (TR). TR is a ligand-regulated transcription factor that is intimately 
associated with chromatin, and also associates with other nuclear proteins to form 
heterodimers. These in turn are bound to target DNAs known as TH-response 
elements (TREs). The formation of a liganded TR/DNA complex leads to activation 
of its associated gene, and to consequentchanges in messenger RNA (mRNA) and 








Thyroid hormone (T4 and T3; TH) exerts numerous effects on the cell. Whereas many 
of its actions involve regulation of gene expression, thyroid hormone may also act at 
the plasma membrane, cytoplasm, mitochondrion, and other non-nuclear sites. T3 and 
T4 may enter the cell by passive diffusion or other poorly defined pathways. In 
addition, T4 may be deiodinated to more active T3 by iodothyronine 5′-deiodinases. 
Furthermore, T3 may be subjected to degradation within the cell. T3 then enters the 
nucleus to bind to the thyroid hormone receptor (TR). The TR, in collaboration with a 
number of other nuclear proteins including the RXRs, form heterodimers that are 
bound to target DNA sites known as thyroid hormone-response elements (TRE). The 
liganded TR/RXR/TRE complex initiates alterations in gene expression among genes 
containing such TREs, and these alterations in turn alter their corresponding mRNA 
and protein levels.(35,36). 
 
 
2.5.1 THYROID HORMONE RECEPTORS 
TRs are ligand-regulated transcription factors that are members of the steroid 
hormone receptor superfamily. TRs are encoded by a protooncogene, c-erbA, and are 
represented by two genomic loci (α and β), located on human chromosomes 17 and 3, 
respectively (37,38).  The T3 response element (TRE) is composed of repeated DNA 
sequences with different configurations. Although TRs can bind to TREs as 
monomers or homodimers, the major form of TR bound to the TRE is the heterodimer 
with retinoid X receptor (RXR) (39). Each TR contains a DNA-binding domain 
(DBD) with zinc finger motifs, and a ligand binding domain (LBD). Ligand binding 
causes major conformational changes in the LBD, that allow TRs to discriminate 
between coactivators and corepressors(40).    The ability to bind specific sequences in 
target genes is crucial for TR function. The consensus sequence recognized by nuclear 
receptors often contains a hexamer AGGTCA known as the half site. Functional and 
efficient binding requires two  of the half-site sequences with different 
configurations.(41,42). TR predominantly bind DNA response elements as 
heterodimers with RXRs Heterodimer formation is thought to enhance DNA-binding 
affinity as well as provide target gene specificity, determined by the spacing between 





2.5.2 MECHANISMS OF TRANSCRIPTIONAL REGULATION 
As a transcriptional factor, a key function of the TR is to regulate the target gene 
expression in response to multiple signaling pathways. TR constitutively bind to DNA 
response elements in the absence and presence of the ligand. Unliganded TR represses 
the basal transcription. Ligand binding causes derepression and enhances 
transcriptional activation. Thus the biological significance of repression is to turn off 
target genes in the absence of hormone and to increase the magnitude of 
transcriptional activation by hormone ligand. A group of cofactor proteins 
(coactivators and corepressors) mediate repression and activation (Figure2.5). 
 
Figure 2.5: Molecular mechanisms of TH action 
 
This diagram illustrates the factors involved in TH action on a TRE in the absence (–
T3 and presence (+T3) of TH. In the –T3 state, TR_RXR heterodimer is bound to a 
TRE that is, in turn, associated with a corepressor. The presence of the corepressor in 
this configuration results in silencing of the associated gene. The direct interaction of 
unliganded TR with the basal transcription factor, TFIIB, may also participate in this 
silencing function. The addition of T3 results in dissociation of the corepressor and 
subsequent association with putative coactivators such as SRC-1 and CBP to result in 
activation of the basal transcription machinery (TFIIB, TFIID, TFIIE and F, RNA 






  Cofactors alone cannot bind DNA but instead they directly interact with DNA-
bound nuclear receptors, as a result of which they are recruited to the proximity of the 
target gene promoter region and affect the rate of transcription. A higher levelA 
higher level of transcriptional regulation is provided by a change of chromatin 
structure. Open chromatin is thought to facilitate the assembly of basal transcriptional 
machinery and increase the transcription rate. In contrast, a highly condensed 
chromatin blocks the entry of TATA-binding protein and leads to transcriptional 
repression. Chromatin structure can be greatly affected by acetylation of histones in 
the nucleosome octamer. Hyperacetylation of histones loosens the interaction between 
DNA and nucleosome opposes the structural change of nucleosomes brought by 
histone acetylation by reducing the net positive charge. Conversely, histone 
deacetylation Both histone acetyltransferase and histone deacetylase activities are 
functionally associated with coactivators and corepressors, respectively, thus 
providing an enzymatic link to the activation and repression by nuclear receptors.(44) 
 
2.6 Regulation of thyroid hormones 
The production of T4 and T3 is regulated by TSH, released by the anterior 
pituitary that is in turn released as a result of thyrotropin-releasing hormone (TRH) 
released by the hypothalamus. As shown in Figure 2.4, the thyroid and thyrotropes 
form a negative feedback loop: TSH production is suppressed when the T4 levels are 
high, and vice versa. The TSH production itself is modulated by TRH, which is 
produced by the hypothalamus and secreted at an increased rate in situations such as 
cold (in which an accelerated metabolism would generate more heat). TSH production 
is blunted by somatostatin (SRIH), rising levels of glucocorticoids and sex hormones 
(estrogen and testosterone), and excessively high blood iodide concentration (45). 
 
By a negative feedback mechanism, increased levels of free thyroid hormones (T4 
and T3) inhibit TSH secretion from the pituitary, whereas decreased levels of T4 and 
T3 cause an increase in TSH release from the pituitary. TSH secretion is also 
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influenced by TRH synthesized in the hypothalamus. TRH causes release of TSH 
(Figure 2.4).  
 
Figure 2.6: Regulation of T3 and T4 secretion (46) 
HPT: hypothalamus, PIT: pituitary, TRH: thyrotropin-releasing hormone,  TSH: 
Thyroid stimulating hormone, TBG: thyroid binding globulin, T4:thyroxine, 
T3:triidothyronine.  
2.7 Thyroid stimulating hormone (TSH) 
TSH stimulates the thyroid gland to secrete the hormones T4 and T3. TSH is a 
glycoprotein which consists of two subunits, the alpha and the beta subunit. The alpha 
(α) subunit is identical to that of hCG, luteinizing hormone (LH), follicle-stimulating 
hormone (FSH). The β (beta) subunit (TSHB) is unique to TSH, and therefore 
determines its function. TSH production is controlled by a TRH, which is 
manufactured in the hypothalamus and transported to the anterior pituitary gland via 
the superior hypophyseal artery, where it increases TSH production and release. 
Somatostatin is also produced by the hypothalamus, and has an opposite effect on the 
pituitary production of TSH, decreasing or inhibiting its release.  The level of thyroid 
hormones (T3 and T4) in the blood have an effect on the pituitary release of TSH; 
When the levels of T3 and T4 are low, the production of TSH is increased and 
conversely, when levels of T3 and T4 are high, then TSH production is decreased 
(47). 
This effect creates a regulatory negative feedback loop.  Determining TSH in the 
serum is a basic search procedure in the diagnosis of the thyroid gland’s function. Its 
regulation is based on feedback, however, during pregnancy there are also other 
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mechanisms taking place (mainly suppression of TSH) presumably due to the thyroid-
stimulating activity of hCG early in pregnancy when hCG levels are the highest (48). 
By using the classic reference interval for serum TSH, one might misdiagnose as 
healthy women who already have a slight TSH elevation and, conversely, one might 
suspect hyperthyroidism in normal women who have a lowered serum TSH value 
(49). 
 
2.8  Thyroid diseases 
2.8.1 Hypothyroidism 
Hypothyroidism is almost due to disease within thyroid gland that causes a 
decrease in the production of thyroid hormones. The most common causes of this 
disorder are shown in Table 2.1. 
 








Women are more predisposed hyopthyroidism than men (53). Hypothyroidism during 
fetal development or early infancy results in cretinism (congenital hypothyridism) 
which causes respiratory difficulties, persistent jaundice, and hoarse crying, stunted 
growth (dwarfism), bone and muscle dystrophy, and mental deficiency in older 
children, and the incidence is 3 times more in girls than in boys. Infants not treated 
within the first 3 months or children within two years suffer irreversible mental 
retardation (54). 
 
2.8.1.1 Symptoms of hypothyroidism 
The signs of hypothyroidism are depending on the organ which is affected. As 
thyroid begins to fail, slight enlargement of thyroid gland (goiter), appearing as a 
lump or swelling, then the patient may begin to feel tired. Some hair loss may be 
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noticed. Then ingernails become thickened, dry, and brittle. Hypothyroidism becomes 
more severe, changes may occur in the tissues beneath skin that lead to a 
characteristic swollen appearance known as myxedema. This is often particularly 
apparent around face and eyes (55).   Circulation is affected and heart rate slows. 
Since intestinal activity slows down, patient may become constipated. A few pounds 
of weight gain may occur. Muscles may become painful with leg cramps.  Nervous 
system may be affected in several ways. Some memory loss may  be noticed, 
decreased ability to think, and depression. Some patients suffer loss of balance and 
difficulty in walking. In women, changes in reproductive system may cause longer, 
heavier, and more frequent menstruation. Their ovaries may stop producing an egg 
each month, and, if so, it may be difficult to get pregnant. So in hypothyroid, many of 
the affected bodily functions simply slow down (56). 
 
2.8.1.2 Diagnosis of hypothyroidism 
Appropriate laboratory evaluation is critical to establish the diagnosis and 
cause of hypothyroidism in the most cost-effective way. The most valuable test is a 
sensitive measurement of TSH level. A TSH assay should always be used as the 
primary test to establish the diagnosis of primary hypothyroidism. Additional tests 
may include the following: 
 
• Free T4 estimate: determination of FT4 is by watching the amount of biologically 
active hormone which is available to the a pregnant woman (as well as the fetus), 
and is not affected by the concentration of binding proteins. Its concentration during 
pregnancy is partly affected by both the inflow of iodine and the duration of the 
pregnancy. Some consider it even more informative than TSH during pregnancy 
(14). The fetus is completely dependent upon thyroxin produced by the mother 
during the first trimester. Even a small unnoticed malfunction of the mother’s 
thyroid gland, which doesn’t necessarily endanger the course of the pregnancy, can 
affect the  psychomotor development of the child (57). 
• Thyroid autoantibodies—anti-thyroid peroxidase and antithyroglobulin 
autoantibodies. 
• Thyroid scan, ultrasonography, or both (if necessary to evaluate suspicious 




2.8.2 Subclinical hypothyroidism    
The term subclinical hypothyroidism is used for patients who have mildly 
increased levels of serum TSH but normal thyroid hormone T4 and T3 levels (59). An 
increase in serum TSH concentration is an early and sensitive indicator of decreased 
thyroid reserve. However, the interpretation of thyroid function tests in the pediatric 
age range is more difficult than in adults. Although normal ranges have been defined 
for all age groups from birth to maturity, significant discrepancies still persist between 
different laboratories. It is therefore important that each laboratory determines its own 
normal values and the results must always be interpreted cautiously (60). It is clear 
that thyroxine therapy is indicated in overt hypothyroidism and uniform agreement 
exists that it is also indicated for patients whose TSH levels are permanently increased 
above 10 mIU/L. For TSH levels between 5 – 10 mIU/L, therapy for these milder 
forms is controversial. In clinical practice some doctors treat all such patients while 
others choose to reassess the thyroid function in 3-6 months to find out if the thyroid 
abnormality is transient. Subclinical hypothyroidism is one spectrum of autoimmune 
thyroiditis, the clinical course is variable and spontaneous remission may occur in 
adolescence (61). Adults with subclinical hypothyroidism, especially with thyroid 
antibodies have been shown to result in overt hypothyroidism with a rate of 5-20 % 
per year. on the  contrary, a very low risk for overt hypothyroidism has been shown in 
children and adolescents during a 5 year follow up (62). 
 
Children and adolescents with type 1 diabetes, with juvenile arthritis and with 
epilepsy who are treated with valproate or carbamazepine are in risk for subclinical 
hypothyroidism and their thyroid function should be followed regularly (63). Early 
detection of subclinical  hypothyroidism with treatment of thyroxine has shown to 
improve growth and metabolic control in type 1 diabetics (64). Increased TSH-levels 
with mildly increased thyroid hormone levels have also been found in up to 15 % of 
obese children and adolescents (65). There is, however, no need to treat these patients, 
hyperthyrotropinemia is reversible after weight loss (66). It has been suggested 
recently that subclinical hypothyroidism is a cardiovascular risk factor in adults and 
physiological thyroxine replacement has a beneficial effect on low density lipoprotein 






Hyperthyroidism is the consequence of excessive thyroid hormone action. The 
causes of hyperthyroidism include the followings (Table 2.2): 
 
Table 2.2: Etiology of hyperthyroidism  (68,69) 
• Toxic diffuse goiter (Graves’ disease) 
• Toxic adenoma 
• Toxic multinodular goiter (Plummer’s disease) 
• Painful subacute thyroiditis  
•  Silent thyroiditis, including  lymphocytic and postpartum 
variations 
• Iodine-induced hyperthyroidism (for example, related to 
amiodarone therapy) 
• Excessive pituitary TSH or trophoblastic disease 
• Excessive ingestion of thyroid hormone  
   
 Globaly every year, 350.000 people develop some kind of hyperthyroidism, and it is 
eight to ten times more common in women than in men (70). 
 
2.8.3.1 Symptoms of hyperthyroidism  
The spectrum of possible signs and symptoms associated with the various 
causes of hyperthyroidism includes nervousness and irritability, Palpitations and 
tachycardia, Heat intolerance or increased sweating, tremor, weight loss or gain,  
alterations in appetite, diarrhea Sudden paralysis,  Exertional intolerance and dyspnea,  
menstrual disturbance (decreased flow), impaired fertility, mental disturbances,  sleep 
disturbances (including insomnia), Changes in vision, photophobia, eye irritation, 
diplopia,  Fatigue and muscle weakness, thyroid enlargement and  Pretibial 
myxedema (in patients with Graves’ disease).  A patient with hyperthyroidism need 







2.8.3.2 Diagnosis of hyperthyroidism 
v A comprehensive history should be elicited, and a thorough physical examination 
should be performed, including the followings: 
• Weight and blood pressure  
• Pulse rate and cardiac rhythm 
• Thyroid palpation and auscultation (to determine thyroid size, nodularity, 
and vascularity) 
• Neuromuscular examination 
• Eye examination (to detect evidence of exophthalmos or ophthalmopathy) 
• Dermatologic examination 
• Cardiovascular examination 
• Lymphatic examination (nodes and spleen) 
 
v Laboratory Evaluation: The development of sensitive TSH assays has 
considerably  facilitated the diagnosis of hyperthyroidism. The sensitive TSH test 
refers to a TSH assay with a functional sensitivity of 0.02 or less. 
Hyperthyroidism of any cause results in a lower-than normal TSH level 
(suppressed TSH). The sensitive TSH assay is the single best screening test for 
hyperthyroidism. Other laboratory and isotope tests may include the 
following(70): 
• T4 or free T4 
• Triiodothyronine (T3) radioimmunoassay (RIA) or free T3 
• Thyroid autoantibodies, including TSH receptor antibodies 
• Thyroid-stimulating immunoglobulins (TSI) 
• Radioactive iodine uptake  
 
2.8.4 Sub clinical hyperthyroidism 
Subclinical hyperthyroidism is an entity that is being increasingly recognized. 
This may be both due to the aging of the population and the development of more 
sensitive TSH. Subclinical hyperthyroidism is defined as the combination of a 
supressed, usually undetectable serum TSH concentration, and normal serum free T3 
and T4 concentrations. The TSH value is measured by an assay with a threshold of 
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detection that is 0.3 mU/L or less (71). Patients with subclinical hyperthyroidism are 
usually euthyroid, but symptoms or signs of thyrotoxicosis such as malaise, 
tachycardia, nervousness and anxiety may be present. In elderly, atrial fibrillation may 
be the initial manifestation. The sensitivity of the pituitary gland to respond to minor 
elevations in serum or tissue T3 and T4 levels is the main pathophysiological 
mechanism of subclinical hyperthyroidism. Abnormal TSH levels may remain for 
years without clinical symptoms of overt hyperthyroidism. The rate of progression of 
subclinical hyperthyroidism to overt disease is at least 1 to 3 percent per year (72). A 
suppression of TSH level may be due to nonthyroidal illness, steroid or dopamine 
administration, or pituitary dysfunction; so, these conditions must be excluded. 
According to its cause, subclinical hyperthyroidism can be classified as endogenous 
and exogenous. The endogenous causes of subclinical hyperthyroidism include 
multinodular goiter, Graves’ disease (early), solitary auto-nomous adenoma, 
thyroiditis and other causes of hyperthyroidism e.g., trophoblastic tumors. The 
exogenous causes of subclinical hyperthyroidism include treatment with  
evothyroxine, exogenous iodine exposure such as recent administration of radio 
contrast material. A 24-hour radioactive iodine uptake will generally be elevated in 
patients with Graves’ disease, multinodular goiter, and solitary autonomous nodule; 
but will be decreased in patients in the hyperthyroid phase of subacute, silent, or 
postpartum thyroiditis and in patients taking excess exogenous thyroid hormone. In 
clinical examination, thyroid gland may be enlarged in some patients, but in most 
patients it is usually normal in size (73). 
 
2.9 Risk factors for thyroid disease: autoimmunity and other conditions 
Several risk factors predispose women to hypothyroidism during pregnancy, including 
autoimmune thyroid disease (AITD), type 1 diabetes mellitus, other endocrine 
deficiencies, Down syndrome, Turner syndrome, thalassaemia major, thyroid 
ablation. and who are treated with pituitary surgery or irradiation, head and neck 
irradiation, treatment of growth hormone deficiency, cytotoxic therapy, lithium, 
interferon α, interferon β, and therapeutic monoclonal antibodies. Patients with a 
family or personal history of thyroid disease, goiter, history of spontaneous abortion, 
Positive thyroid peroxidase antibody, origin from areas of endemic iodine deficiency,  
Previous thyroid disease or surgery, or any symptoms suggesting hypothyroidism, are 
at higher risk for hypothyroidism. Recent studies have suggested that AITD 
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independent of hypothyroidism, may have adverse effects, which include increased 
risk of miscarriages and recurrent miscarriages, fetal death, and possible effects on 
childhood cognition, and postpartum depression (74, 75). 
 
2.10 Maternal thyroid physiology 
The high circulating estrogen levels during pregnancy change the pattern of 
glycosylation of TBG at the time of hepatic synthesis, leading to a longer plasma half-
life and, consequently, an increase in the plasma TBG concentration(76) This lead to 
increased serum T4-binding globulin and T4 concentrations (77                                                                                                
, 50, 78 ). Although a transient decrease in serum free T4, followed by a rise in TSH to 
a new equilibrium, may occur (79), this is usually not appreciated with routine thyroid 
testing. A high circulating hCG level in the first trimester leads to hCG cross-
reactivity with the TSH receptor, prompting a temporary increase in free T4 and partial 
suppression of TSH. The final physiologic change results from placental deiodination 
of maternal T4, which increases T4 turnover. In normal pregnant women, the thyroid 
gland maintains euthyroidism with only minor fluctuations in serum T4 and TSH. 
However, in women with limited thyroid reserve, due to thyroid autoimmunity or 
iodine deficiency, hypothyroidism can develop. Fetal thyroid ontogeny begins at 10–
12 weeks gestation and is not complete until delivery; T4 is not secreted until 18–20 
weeks (77, 78). T4 is critical for many aspects of brain development including 
neurogenesis, neuronal migration, axon and dendrite formation, myelination, 
synaptogenesis, and neurotransmitter regulation (79). Although these requirements 
evolve over months (80), an especially critical time is the second trimester (81).  
 
2.11 Fetal thyroid physiology and the effect of maternal thyroid status 
Fetal thyroid function occurs from the end of the first trimester. Prior to that, there is 
evidence that normal development of the fetal brain is dependent upon maternally 
derived T4, which is converted intracellularly to T3. Such T4 has been detected from 
5-8 weeks’ gestation and by 11 weeks it is at 100 times greater concentration than in 
the maternal circulation. Maternal hyothyroxinaemia at this stage may have adverse 
effects on subsequent fetal brain development. Fetal FT4 and total T4 reach adult 
levels by 36 weeks  gestation, fetal TSH is greater than adult TSH and fetal T3 
remains low. The relatively high levels of T4 allow intracellular conversion to T3 in 
the fetal brain. When fetal thyroid dysfunction occurs, maternally derived T4 becomes 
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essential to allow normal neurological development. Placental perfusion studies have 
demonstrated that, in normal pregnancy at term, very little (0.008%) maternal T4 
crosses to the fetal side; inhibition of placental deiodination of T4 enhances transfer 
2700-fold, so that fetal levels reach 30% of maternal concentrations. In pregnancy 
complicated by fetal thyroid dysfunction, deiodinase III is inhibited, allowing 
additional transfer of T4 to the fetus, reduced fetal peripheral deiodination of T4 and 
enhanced intracellular  activation to T3 in the fetal brain, so protecting it from 
permanent damage.(82) 
 
2.12 Regulation of thyroid function during normal pregnancy 
2.12.1  Increase in thyroid-binding globulin 
In conditions with TBG excess, such as pregnancy, the proportion of 
circulating T4 carried by TBG is even greater, in excess of 75%, which indicates that 
TBG represents the major thyroid hormone transport protein in pregnancy (83). 
During pregnancy the respective affinities of the three binding proteins for their 
hormonal ligands are not significantly modified, and the circulating levels of both 
serum albumin and transthyretin remain stable, with only a slight tendency to 
decrease near the end of gestation, mainly as a result of passive hemodilution due to 
the increased vascular pool (84). Thus, the major change for thyroid hormone-binding 
proteins involves the marked and rapid increase in serum TBG levels as a result of 
estrogen stimulation. Compared with preconception concentrations (average 15–16 
mg/liter), serum TBG begins to increase in pregnancy after a few weeks and reaches a 
plateau around midgestation, 2.5-fold higher than the initial value, between 30–40 
mg/liter (85, 86, 87 ). The mechanism for this increase in TBG involves both an 
increase in hepatic synthesis of TBG and an estrogen-induced increase in sialylation, 
which increases the half-life of TBG from 15 min to 3 days for fully sialylated. TBG 
that lead to lowered free T4 concentrations, which results in elevated TSH secretion 
by the pituitary and, consequently, enhanced production and secretion of thyroid 
hormones. The net effect of elevated TBG synthesis is to force a new equilibrium 
between free and bound thyroid hormones and thus a significant increase in total T4 
and T3 levels. The increased demand for thyroid hormones is reached by about 20 






2.12.2 Increases in total T4 and T3 
In pregnancy, the alterations in total TH levels are the direct consequence of 
the marked increase in serum TBG: total T4 and T3 levels increase significantly 
during the first half of gestation. Levels of serum T4 rise sharply between 6 and 12 
weeks, progress more slowly thereafter, and stabilize around midgestation,  for serum 
T3, the rise is more progressive (89). Both total T4 and T3 reach their plateau values 
by 20 weeks and are maintained until term because of the 20-fold greater affinity of 
TBG for T4 compared with T3, changes in T4 levels follow the changes in TBG more 
closely. It can be expected therefore that the T3/T4 molar ratio should remain 
essentially unaltered during pregnancy (90,91). The etiology of this increase in total 
circulating thyroid hormones involves, primarily, increased concentrations of plasma 
TBG. Another proposed mechanism for this increase in total thyroid hormone 
concentrations is production of type III deiodinase from the placenta. This enzyme, 
which converts T4 to reverse T3, and T3 to diiodotyrosine (T2), has extremely high 
activity during fetal life. Increased demand for T4 and T3 has been suggested to 
increase production of these hormones with, ultimately, increased concentrations in 
the circulation. The increase in T4 and T3 concentrations is less than would be 
expected by the increase in TBG as a relative hypothyroxinemia (92). On average, 
pregnant women had lower free hormone concentrations at term than non pregnant 
women. Other studies have confirmed that serum free T4 and T3 are ~25% lower in 
women at delivery than non pregnant subjects. However, most pregnant women 
(>78%) remain within the same reference interval as non pregnant women (93). 
 
2.12.3 Thyroid stimulation by hCG  
HCG is a member of the glycoprotein hormone family that is composed of a 
common α-subunit and a hormone-specific β-subunit, non-covalently associated. The 
α-subunit of hCG consists of a polypeptide chain of 92 amino acid residues containing 
two N-linked oligosaccharide side-chains. The hCG β-subunit consists of 145 residues 
with two N-linked and four O-linked oligosaccharide side-chains. The TSH β-subunit 
is composed of 112 residues and one N-linked oligosaccharide. The β-subunits of 
both possess 12 half-cysteine residues at highly conserved positions. Three disulfide 
bonds form a cystine knot structure, which is identical in both TSH and hCG and is 
essential for binding to their receptor (LH and hCG bind to the same receptor). The β-
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subunit has strong homology with LH, but it also has a C-terminal tail peptide that 
contains 4 O-linked oligosaccharide units that contribute substantially to its molecular 
weight (94).  
 
A single gene on chromosome 6 encodes for the common α-subunit, while the 
genes that encode for the β-subunits are in a cluster on chromosome 19, with seven 
genes (but only three actively transcribed) coding for βhCG (95, 96, 97).  Serum hCG 
rises exponentially during the first trimester of pregnancy, peaking at 10 to 12 weeks 
of pregnancy (98). During a normal pregnancy, the direct stimulatory effect of hCG 
on the thyroid induces a small and transient increase in free thyroxine levels near the 
end of the 1st trimester (peak circulating hCG) and in turn a partial TSH suppression.  
In bioassays, hCG is only about 1/104 as potent as TSH during normal pregnancy. 
This weak thyrotropic activity explains why, in normal conditions, the effects of hCG 
remain largely unnoticed and thyroid function tests unaltered (4). When hCG is at its 
greatest concentration, serum TSH concentrations drop, creating the inverse image of 
hCG. In most pregnancies, this decrease in TSH remains within the health-related 
reference interval. Under pathological conditions in which hCG concentrations are 
markedly increased for extended periods, significant hCG-induced thyroid stimulation 
can occur, decreasing TSH and increasing free hormone concentrations (99).  
 
2.12.4 Increase in renal iodide clearance 
Iodine is available from maternal circulation to the fetal-placental unit. The 
extent of iodine passage from mother to fetus has not yet been precisely established. 
At  gestation, the fetal thyroid gland has already started to produce thyroid hormones 
that are indispensable for an adequate development of the fetus (100). The main 
changes in thyroid function associated with pregnancy are related to  increased 
hormone requirements, which begin in the first trimester of gestation. Increased 
hormone requirements can only be met by proportional increased hormone 
production, directly depending upon the availability of iodine in the diet. When iodine 
nutrition levels are sufficient, physiological adaptation takes place. Furthermore, 
iodine deficiency may be associated with alterations of the neuropsychointellectual 
outcome in the progeny, and the risk for an abnormal development of the progeny is 
further enhanced because both the mother and offspring are exposed to the deficiency 
not only during the entirety of gestation but also during the  postnantal period (101). 
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In pregnancy, the renal clearance of iodide increases substantially because of an 
increased glomerular filtration rate. The iodide loss lowers the circulating 
concentrations of iodide and produces a compensatory increase in thyroidal iodide 
clearance. In areas of the world where iodine intake is sufficient, such as the US, the 
iodide losses in the urine are not clinically important. In other areas of the world, 
however, iodine deficiency during pregnancy can lead to hypothyroidism and goiter 
and poses a serious public health issue. Approximately 500 million people live in 
areas of overt iodine deficiency. In the non pregnant condition, adequate iodine intake 
is estimated to be 100–150 μg/day. The World Health Organization recommends that 
during pregnancy, iodine intake be increased to at least 200 μg/day (102). 
 
2.12.5 Increase in serum thyroglobulin 
Thyroglobulin frequently is increased during pregnancy, reflecting the 
increased activity of the thyroid gland during pregnancy. The increase in 
thyroglobulin can be seen as early as the first trimester, but it is more pronounced in 
the latter part of pregnancy. Increased serum thyroglobulin concentrations are also 
associated with an increase in thyroid volume. Despite this, goiter, as defined by 
thyroid volume >23 mL, occurs in only 5–15% of women at term. This low incidence 
is likely attributable to adequate intake of dietary iodine (103). A summary of changes 
in the thyroid tests during pregnancy are given in Table 2.3. 
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2.13 Hyperthyroidism during pregnancy 
The incidence of hyperthyroidism in pregnant women has been estimated at 0.2% 
and is mostly caused by Graves’ disease.(52) Most women have symptoms before 
pregnancy, but some will demonstrate symptoms for the first time during pregnancy. 
The most common causes  are shown in Table 2.4.  
Table (2.4): Etiology of hyperthyroidism in pregnancy (51, 104) 
 
Maternal complications include miscarriage, abruptio placenta, and preterm delivery. 
Congestive heart failure and thyroid storm may also occur and the risk of 
preeclampsia is significantly higher in women with poorly controlled 
hyperthyroidism. 
2.14 ypothyroidism during pregnancy 
The incidence of hypothyroidism in pregnant women has been estimated to be 
0.3–0.7%  (50). There is a known association between hypothyroidism and decreased 
fertility (105–107). For this reason, the frequency of hypothyroidism in pregnancy is 
actually lower than the 0.6–1.4% frequency in the general population (50 ). Causes of 
hypothyroidism during pregnancy are listed in Table(2.5). 




Primary atrophic hypothyroidism 
Infiltrative disease (e.g., sarcoid, amyloidosis) 
TSH-dependent hypothyroidism 
 
Graves disease (85–90% of all cases) 
Sub-acute thyroiditis 
Toxic multinodular goiter 
Toxic adenoma 
TSH-dependent thyrotoxicosis 







2.15 Related studies 
To evaluate the incidence of thyroid function disorder in Singaporean 184 
unselected pregnant women who were in their 8th to 14 th weeks of pregnancy were 
tested for  Serum F T4, F T3, TSH. Two subjects (1·1%) were found to have Graves' 
disease and  elevated free T4, free T3 and suppressed TSH were seen in 14·8%, 3·3% 
and 33·0% of the remaining 182 pregnant women, respectively. 11·0% of cases had 
gestational thyrotoxicosis (GT) defined as elevated free T4 (> 19·1 pmol/l), 
suppressed TSH (< 0·36 mIU/l). The prevalence of GT was significantly higher in 
patients tested at 8–11 weeks compared to those evaluated at 12–14 weeks (14·4% vs. 
4·7%, P < 0·05). and free T4 (P = 0·02) levels were higher and TSH levels (P = 0·01) 
lower in patients tested at 8–11 weeks.(109) 
 
To evaluate serum levels of TSH in 124 pregnant women. The women were 
apparently normal, healthy young primigravidas. consecutively attending the antenatal 
clinic were included in the study. Mean TSH levels was 1.20 microlU/ ml. Three 
asymptomatic pregnant women (2.5%) were found to have abnormal TSH. the values 
with normal T3 and T4 levels where normal obstetric outcome was good.  (110) 
 
The incidence of thyroid disorder in Tunisian determined TSH and TPO-Ab in 
1519 pregnant women aged 17 to 47 years. Thyroid disorder was defined as 
hyperthyroidism (TSH≤0.10 mIU/L) or hypothyroidism (TSH >4.5 mIU/L), and/or 
positive TPOAb (>12 IU/L). Thyroid disorders were observed in 147 pregnant 
women (9.7%). Positive TPO-Ab was noted in 99 women (6.5%), hypothyroidism in 
48 thyroid disorders women (3.2%) and hyperthyroidism in 10 women (1.3%). (111) 
 
A screening study for 4800 China  women during the first half of pregnancy..    
They were screened for thyrotropin, free thyroxine and thyroid peroxidase antibody. 
Two different series of reference intervals for TSH and FT4,were calculate, the 
gestational age-specific reference intervals (S1) and non-pregnant population 
reference intervals (S2) were used to diagnose thyroid dysfunction. The S2 of serum 
TSH was 0·3–4·8 mIU/L, FT4 was 10·3–24·5 pmol/L. hormone deficiency as the 
prevalence of subclinical hypothyroidism at 4, 8, and 12 weeks of gestation was 
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4.59%, 6.15%, 4.68%, respectively, and the prevalence of hypothyroxinaemia was 
3.69%, 1.11%, 2.92%, respectively.(112)  
 
A Study in Tabriz-Iran (2005) was  carried out to find out alterations in 
thyroid function tests in each trimester in normal pregnant women as compared to 
non-pregnant women. A case-control study designed with 229 normal pregnant and 
250 randomly selected non-pregnant healthy female controls. Age range in both 
groups was 16-40 years. Thyroid function tests carried out by measuring serum levels 
of TSH, FT4, and FT3. They  found that mean FT4 was strongly decreased during the 
third trimester. Free T3 showed declining in the second and third trimesters. Mean 
TSH did not show significant difference in each trimester compared with non-
pregnant women.. The thyroid function test for Non-pregnant women N=250 was FT4 
pmol/L 14.40±10.46 ,  FT3 pmol/L 5.25±2.89 and TSH  1.93±1.04 µU/L.  Pregnant 
Women First trimeste N=64 thyroid function test was FT4 pmol/L 14.90±4.67,    FT3 
pmol/L 6.84±2.02and TSH  µU/L 1.71±1.38. (113) . 
 
 
To study the influence of pregnancy on the results of free thyroxin 
measurement. Thirty-eight healthy pregnant women were enrolled in the study. Serial 
TSH, free thyroid hormone, total thyroid, HCG, and thyroid autoantibody levels. Data 
of 19 individuals were analyzed.  An increase of total T3 and T4 levels was observed 
parallel with changes of TBG concentration during the first 4 months of gestation. 
Serum TSH time-curve showed a transient fall in the first trimester, thereafter it 
returned to the non-pregnant values. Curves of serum TSH and hCG created clear 
mirror images. Free T4 concentrations elevated in line with the HCG peak at the 
beginning of gestation, thereafter it clearly followed the course of serum TSH. Free 
T3 levels gradually decreased throughout pregnancy.  The negative correlation 
between HCG and TSH levels, and the clear identity of the hCG +TSH and free T4 
curves (114). 
 
A Study was conducted in Geneva (2007) using surplus, de-identified serum 
specimens collected from pregnant women. A total of 2272 samples were included in 
the study.  For the first trimester, mean maternal and median gestational age was 30.4 
years and 7.6 weeks respectively. Of these women, 21.4% were positive for TPO-Ab 
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and/or Tg-Ab; 10.8% were TPO-Ab positive and 17.3% were Tg-Ab positive.  TSH 
for  First trimester (<6–12)  weeks 0.8666(mU/l)  for ≤6 weeks  the mean was1.1946  
while  the mean was 0.7716  for>6-12 weeks.  Manufacturer’s non-pregnant reference 
interval is 0.35–4.94 mIU/l. Free T4 (pmol/l) First trimester (<6–12) weeks the mean 
was 13.96 for ≤6 weeks the mean was 13.68 and for >6-12 weeks the mean was 14.06 
.Manufacturer’s non-pregnant reference interval is 9.01–19.05 (pmol/l). Free T3 
(pmol/l) First trimester( < 6–12) weeks the mean was 4.73 for≤6 weeks the mean was 
4.63, And for >6-12 weeks the mean was 4.52 .Manufacturer’s non-pregnant 
reference interval is 2.63–5.70 (pmol/l) (115). 
 
In another study in India performed a case-control study designed with two 
groups of women: 75 normal pregnant women randomly selected from the first  and 
75 randomly selected non-pregnant healthy female controls. Thyroid function tests 
were carried out by measuring the serum levels of (TSH), (FT4), and (FT3). The 
results for  TSH, FT4 and FT3 were 2.54 ± 1.32 (mIU/ml),   15.10 ± 11.56 (pmol/L ) 
and  6.21 ± 3.10 (pmol/L) for non-pregnant women respectively. While the results of 
pregnant womens TSH 1.93 ± 1.53 (mIU/ml), FT4( 14.93 ± 3.77) (pmol/L )and FT3 
7.11 ± 2.32 (pmol/L ). The mean FT4 levels in the first trimesters were non-
significantly lower than that of the non-pregnant subjects. The pregnant groups' mean 
FT3 non-significantly higher than that of the non-pregnant subjects, the mean TSH 




A studied of 118 healthy pregnant women living in an iodine-sufficient area. 
pregnant women with the mean age 30.9 ± 4.1 years in the first trimester. mean 11.2
± 2.5 weeks of pregnancy), in the third trimester (mean 31.6 ± 1.7 weeks of 
pregnancy), All women were negative for thyroid autoantibodies .TSH was measured.  
Results: TSH concentration was significantly higher in the third trimester than in the 
first trimester (P = 0.007).(117) 
 
 
To investigate the relationship between TSH and FT4, a study on  5520 women 
during the first trimester of pregnancy for serum TSH and FT4. Results: The reference 
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interval for TSH was determined to be 0.06–3.67 mU/l. The suppression of TSH was 
found in 2.93% of the women; a raised concentration of TSH had been found in 
4.48% of the women. FT4 was determined only for women (n=697) with TSH lower 
than 0.1, for FT4 reference interval of 9.8–23.1 pmol/l for all populations. There were 
30 (4.3%) women with FT4 under and 18 (2.5%) women with FT4 over the reference 
interval..(118) 
 
In study in United States where a total of 10,990 patients had first- and 
second-trimester serum assayed for TSH, free T4), and antithyroglobulin and 
antithyroid peroxidase antibodies. Thyroid hypofunction was defined as 1) subclinical 
hypothyroidism: TSH levels above the 97.5th percentile and free T4 between the 2.5th 
and 97.5th percentiles or 2) hypothyroxinemia: TSH between the 2.5th and 97.5th 
percentiles and free T4 below the 2.5th percentile. Subclinical hypothyroidism was 
documented in 2.2% (240 of 10,990) in the firsttrimester . Hypothyroxinemia was 
documented in 2.1% (232 of 10,990) in the first Subclinical hypothyroidism was not 

































MATERIALS AND METHODS 
 
3.1 Study design 
The present study is a cross Sectional       
3.2 Target population 
The target population was pregnant women in the  first trimester  from AL- Rimal 
Health Clinic, Gaza city. 
 
3.3 Sampling and sample size 
A total of 90 apparently  healthy   pregnant  women aged 18-40 years  in their 1–13th 
week of  pregnancy were selected  gestational ages were calculated based on the dates 
of their last menstrual period and findings from an ultrasound scan.  The control 
group comprised 80 randomly selected non-pregnant healthy females of childbearing 
age.  
3.4 Eligibility 
3.4.1 Inclusion criteria 
Healthy, pregnant women during the first trimester, gestational age 18-40 years and 
reside in Gaza city. 
3.4.2 Exclusion criteria 
Women who were diagnosed or treated for thyroid dysfunction, aged less than 









3.5 Ethical considerations 
The researcher obtained the necessary approval to conduct the study from Helsinky 
committee (Annex 1). Coordination with the Ministry of Health was fulfilled (Annex 2). 
Informed consent was obtained from parents of all the participants. A full explanation 
about the purpose of the study, assurance about the confidentiality of the blood analysis, 
and the right to refuse or to participate (Annex 3) in the present study were given. 
 
3.6 Questionnaire design 
A face to face meeting between the researcher and subjects was the method of filling 
the questionnaire. The questionnaire includes personal data (e.g. age, address), 
number of miscarriages , number of pregnancies, thyroid problems, and receiving any 
medication and so on.  (Annex 3). 
 
3.7 Pilot study 
Pilot study was done before the study started to evaluate the clarity of the 
questionnaire and to optimize the techniques. Ten pregnant women during the first 
trimester and a similar number of non pregnant women  were interviewed, and blood 
samples were collected from them. At the end  of the pilot study, a revision and 
modification was done on questionnaire as necessary. 
 
3.8 Blood sampling and processing 
Under quality control and safety procedure for sample collection, 5 ml venous blood 
sample was collected from 90 pregnant women during the first trimester in plain 
vaccutainer tubes. Also, 5ml venous blood samples were collected from 80 non 
pregnant women. Serum was separated from whole blood for all specimens using fine 
centrifugation at 3000 rpm for 15 min. Serum samples were sent to the lab within 2 
hours of collection, for analysis. Serum samples were assayed for TSH ,FT4 and FT3 








3.9 Biochemical analysis 
3.9.1 Determination of serum TSH 
In the present study serum TSH was determined using a Microparticale Enzyme 
Immunoassay Technology. For this purpose Abbot full–automated Axsym immunoassay 
analyzer TSH assay system (Abbott laboratories, USA.) was used. 
• Principles 
AxSYM Ultrasensitive hTSH II is based on the Microparticle Enzyme Immunoassay 
(MEIA) technology. The AxSYM Ultrasensitive hTSH II reagents and sample are 
pipetted in the following sequence. 
• Sampling  
v Sample and all AxSYM Ultrasensitive hTSH II reagents required for 
one test are pipetted by the Sampling Probe into various wells of a 
reaction vessel (RV). 
v Sample and Anti-hTSH Coated Microparticles are pipetted into one 
well of the RV forming an antibody-antigen complex. The RV is 
immediately transferred into the Processing Center. Further pipetting is 




v An aliquot of the reaction mixture containing the antibody-antigen 
complex bound to the microparticles is transferred to the matrixcell. 
The microparticles bind irreversibly to the glass fiber matrix. 
v The matrix cell is washed with the LDS Wash Buffer. 
v The Anti-hTSH: Alkaline Phosphatase Conjugate is dispensed onto the 
matrix cell and binds with the antibody-antigen complex. 
v The matrix cell is washed to remove unbound materials. 
v The substrate, 4-Methylumbelliferyl Phosphate, is added to the matrix 









v Bottle (14.1 mL) Anti-hTSH (Goat): Alkaline Phosphatase Conjugate 
in TRIS buffer with protein (bovine) stabilizers. Minimum 
concentration: 0.1 μg/mL. Preservative: Sodium Azide. 
v Bottle (9.0 mL) Anti-hTSH (Mouse, Monoclonal) Coated 
Microparticles in TRIS buffer with protein (bovine) stabilizers. 
Preservative: Sodium Azide.  
v Bottle (21.5 mL) LDS Wash Buffer containing surfactant. 
v Bottle (47 mL) TRIS Buffer. Preservatives: Sodium Azide and 
Antimicrobial Agents.  
• Expected values 
The suggested normal range of the AxSYM Ultrasensitive hTSH II Assay is 
0.5-5 μIU/mL. 
 
3.9.2 Determination of serum FT4 
AxSYM Free T4 is a Microparticle Enzyme Immunoassay (MEIA) for the 
quantitative determination of free thyroxine in human serum orplasma. 
• Principles 
v AxSYM Free T4 is based on Microparticle Enzyme Immunoassay 
(MEIA) technology. 
v The AxSYM Free T4 Reagents and samples are pipetted in the 
following sequence 
• Sampling  
v Sample and all AxSYM Free T4 reagents required for one test are 
pipetted by the Sampling Probe into various wells of a reaction vessel 
(RV). 
v The RV is immediately transferred into the Processing Center. Further 
pipetting is done in the Processing Center with the Processing Probe. 
• Procedure 
v Sample and Anti-T4 Coated Microparticles are pipetted into one well 
of the RV forming an antibody-antigen complex. 
v An aliquot of the reaction mixture containing T4 bound to Anti-T4 
Coated Microparticles is transferred to the matrix cell. The 
microparticles bind irreversibly to the glass fiber matrix. 
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v The matrix cell is washed with Solubilizer Solution to remove unbound 
materials. 
v The T3: Alkaline Phosphatase Conjugate is dispensed onto the matrix 
cell and binds to the unoccupied antibody binding sites. 
v The matrix cell is washed to remove unbound materials. 
v The substrate, 4-Methylumbelliferyl Phosphate, is added to the matrix 
cell and the fluorescent product is measured by the MEIA optical 
assembly. 
• Reagents 
v AxSYM Free T4 Reagent Pack 
v Bottle (15.2 mL) Solubilizer Solution. TRIS buffer containing 
surfactant. Preservative: Sodium Azide.  
v Bottle (12.8 mL) T3: Alkaline Phosphatase Conjugate in TRIS buffer 
with protein stabilizers. Minimum concentration: 0.4 ng/mL. 
Preservative: Sodium Azide.  
v Bottle (14.4 mL) Anti-T4 (Sheep) Coated Microparticles in TRIS 
buffer with protein stabilizers. Preservative: Sodium Azide. 
v Bottle (50.2 mL) TRIS buffer. Preservatives: Sodium Azide and 
v Antimicrobial Agents. 
 
• Expected values 
The suggested normal range for AxSYM Free T4 is 0.6-1.6 ng/dL. 
 
 3.9.3 Determination of serum FT3 
AxSYM Free T3 is a Microparticle Enzyme Immunoassay (MEIA) for the 
quantitative determination of free triiodothyronine (free T3) in human serum or 
plasma on the AxSYM System. 
• Principles 
 
AxSYM Free T3 is based on the Microparticle Enzyme Immunoassay (MEIA) 






• Sampling  
v Sample and all AxSYM Free T3 reagents required for one test are 
pipetted by the Sampling Probe into various wells of a reaction vessel 
(RV). 
v The RV is immediately transferred into the Processing Center. Further 
pipetting is done in the Processing Center by the Processing Probe 
• . Procedure 
v Sample and Anti-T3 Coated Microparticles are combined in one RV 
well. 
v The free (unbound) T3 in the sample binds to the Anti-T3 Coated 
Microparticles forming an antibody-antigen complex. 
v An aliquot of the reaction mixture, containing the antibody-antigen 
complex bound to the microparticles, is transferred to the matrix cell. 
The microparticles bind irreversibly to the glass fiber matrix. 
v The T3:Alkaline Phosphatase Conjugate is dispensed onto the matrix 
cell and binds to the available sites on the Anti-T3 Coated 
Microparticles. 
v The matrix cell is washed to remove unbound materials. 
v The substrate, 4-Methylumbelliferyl Phosphate, is added to the matrix 
cell and the fluorescent product is measured by the MEIA optical 
assembly. 
• Reagents 
v AxSYM Free T3 Reagent Pack 
v Bottle (13.95 mL) LDS Wash Buffer containing surfactant. 
v Bottle (13.55 mL) T3 :Alkaline Phosphatase Conjugate in TRIS Buffer 
with protein (bovine) stabilizers. Minimum concentration: 0.4 ng/mL. 
Preservative: Sodium Azide.  
v Bottle (10.16 mL) Anti-T3 (Sheep, Monoclonal) Coated Microparticles 
in TRIS Buffer with protein (bovine and ovine) stabilizers. 
Preservative: Sodium Azide. 







• Expected values 
The suggested normal range for AxSYM Free T3 1.8 to 4.7 pg/mL  
 
3. 10 Statistical analysis 
Data were computer analyzed using SPSS/PC (statistical package for the 
social science Inc., Chicago, Illinois USA, version 16.0). 
 
• Data analyses were carried out as follow 
v Over viewing field questionnaire. 
v Coding of questionnaire. 
v Choosing data entry mode and data entry. 
v Data cleaning. 
v Defining and re-coding of certain variables. 
 
Results were expressed as a mean ± SD. For comparison of the obtained 
variables between the study periods, we performed the Kruskal–Wallis rank test and 
x2-test. Spearman’s analysis was used to calculate the correlation coefficients. The 
Kologorov-Simirnove assess the normality of three variables among each group. one 
way ANOVA test is used.  P value < 0.05 was marked as statistically significant. 
 
 





























4.1 Characteristics of the study population 
The present study is a cross sectional study, that included 170 women 90 pregnant 
and 85 non pregnant, from Gaza city. The mean age of pregnant was 24.9  years, and 
that of the non pregnant group was 29.3 years. The mean of gestational  age of  the 
cases was 8.7 weeks. The mean number of pregnancies for pregnant and  non 
pregnant group was 3.5, 3.9 times, respectively and the mean number of abortions 
was 0.47 and 0.43 times, respectively (Table 4.1). 
 
Table 4.1 General information of the pregnant and non pregnant groups. 
pregnant(n=90) (n=80)non pregnant Parameters 
Mean S. D Mean S. D 
Age (years) 24.9 5.6 29.3  5.4 
Gestational  age (weeks)  8.7  3.2 0.0 0.0 
Number of pregnancies (times)  3.5 2.6 3.9 2.5 
Number of abortions (times) 0.47 0.88 0.43 0.91 
 
4.2 Serum TSH,  FT4 and FT3 status in the study population 
 
Table 4.2 indicated that 4 (2.4 %) of study population had elevated TSH levels 
(>5mIU/ml). 2 (2.2 %) in pregnant and 2 (2.5 %) in non pregnant so. Elevated FT4 
level was found only in one pregnant (0.6%). Twelve subjects (7.1%) had elevated 
FT3 levels. 11 (12.9%) in pregnant and 1 (1.1%) in non pregnant.  
 
Table 4.2 Thyroid stimulating hormone(TSH), FT4 and FT3 status in the study 
population.(n=170)  






TSH(mIU/ml) 4 (2.4) 2.0 (2.2)  2.0(2.5) 
FT4( ng/d)  1 (0.6) 1 (0.6)  0.0 







4.3 Serum thyroid hormone levels  in pregnant and non- pregnant women 
The mean of thyroid hormones in pregnant women in the first trimesters as 
well as, in non pregnant are shown in Table 4.3. There was no significant difference 
in the mean level of TSH between pregnant and non pregnant (mean =1.9 ±1.2 
Vs1.9±0.94 mIU/ml, t=0.212, p=0.832). on other hand, the mean levels of FT4 and 
FT3 significantly increased in pregnant compared to non pregnant (mean = 0.96±0.30 
and  3.1 ±1.4 Vs 0.88±0.19 ng/d and 2.7±0.69 pg/ml, p=0.041, 0.030, respectively). 










TSH(mIU/ml) 1.9 1.2 1.9 0.94 0.212 0 0.832 
FT4 ( ng/d) 0.96 0.30 0.88 0.19 2.058 -9.1 0.041 
FT3 (pg/ml) 3.1 1.4 2.7 0.69 2.199 14.8- 0.030 
p> 0.05: not significant.  
p<0.05: significant. 
4.4  The Relation between  thyroid hormones and pregnancy  
The independent t-test showed that patients who suffer from thyroid problem 
had decreased mean levels of TSH compared to those who had not suffer ones(1.6± 
0.36 Vs1.9±1.2 mIU/ml). These changes were not significant (t = 0.507, p =0. 6140) 
on other hand, the mean levels of FT4 and FT3 didn’t  also significantly between who 
suffer from thyroid problem and who had not (0.96 ±0.10 ng/d, 3.2±0.38  pg/ml Vs 
0.96±0.31 ng/d, 3.1±1.4 pg/ml, p=0.730, p=0 .966, respectively). 
Table :4.4 Results  of thyroid   hormones in pregnant   women. 
p-value  t  
% 
Difference Std. 
Deviation  Mean  n  
Are there problems 
in the thyroid gland  
  
0.36  1.6  3 Yes  
.6140  0.507  
  
18.8- 1.2  1.9  87  No  
TSH 
mIU/ml)(  
0.10  0.96  3  Yes  .7300  0.346 0 0.31  0.96 87  No  FT4 ( ng/d)  
0.38  3.2  3 Yes 
.9660  0.043 
  
3.1  
 1.4  3.1 87  No  
  
FT3(pg/ml) 






Table 4.5 demonstrates there was no significant difference in the mean level of 
TSH between who had not suffer from thyroid problem and who had suffer ones 
(1.9±0.87 Vs 3.1±2.02,  p=0.912). Patients who had not suffer from thyroid problem 
had increased mean levels of FT4 compared to those who had suffer ones 
(0.86±0.19Vs 0.77±0.29 ng/d). However such changes were not significant (p=0.233). 
LikeFT3 were slightly decreased in Patients who had not suffer from thyroid problem 
compared to those who had suffer ones(2.7±0.66 Vs2.9±1.4pg/m), but these changes 
were not significant(p=0.566) 
Table 4:5 Results  of thyroid   hormones in the non pregnant. 
p-value 
% 
Difference Std. Deviation  Mean  n  
Are there problems in 
the thyroid gland  
  
.870  1.9  77   No  0.912  
38.7 
2.02  3.1  3 Yes  
TSH 
(mIU/ml)  
.190  .860  77 No  .2330  11.7- .290  0.77  3  Yes  
FT4 
( ng/d)  
.660  2.8  77 No 
0.566  
3.4  
1.4  2.9 3 Yes  FT3(pg/ml) 
p> 0.05: not significant.  
p<0.05: significant. 
 
4.5 Assessment of thyroid hormones. 
The mean levels of TSH, FT4 and FT3 for who had previous thyroid problem 
compared to those who had not are presented in Table 4.6. The mean level of TSH, 
FT4 and FT3 for those had previous thyroid problem(1.7±0.64mIU/m, 0.93±0.30ng/d 
, 3.1±0.95pg/m respectively ) was found not significantly lower than that in those who 












Table4:6 Assessment of thyroid hormones .in pregnant population who had 
previous thyroid problem.  
 




Deviation Mean n 
Previous Thyroid 
problems 
0.64  1.7  3 Yes  
.7550  .3130  
11.7- 
1.2 1.9 87  No 
TSH 
mIU/ml)(  
0.30  0.93  3  Yes  0.879  0.152  3.2- 0.30 0.96 87 No FT4( ng/d) 
0.95  3.1  3  Yes  
0.901 0.124 
0 
1.4 3.1 87 No 
FT3(pg/ml) 
  
p> 0.05: not significant.  
p<0.05: significant. 
 
Table 4:7 illustrates the mean levels of TSH for who had not previous thyroid 
problem(1.94±0.88mIU/ml) was found not significantly lower than that compared to 
those who had ones in control population(2.6±1.75mIU/ml) showing p=0.630. On the 
other hand, no significant change was observed in the mean levels of FT4 and FT3 
between who had not previous thyroid problem and those who had ones(0.89±0.19 
Vs0.77±0.29 ng/d, 2.8±0.66, 2.8±1.2pg/m, p=0.208,p=0.477 respectively). 
 
Table 4:7 Assessment of thyroid hormone .in non pregnant population who had 












Is there an analysis of 
the thyroid gland  
.880  1.9  77 No  
.6300  
26.9 
1.8.  2.6  4  Yes  
TSH 
(mIU/ml) 
0.19  .890  77 No  .2080  15.5- 0 .29  .770  4  Yes  FT4( ng/d)  
.660  2.8  77 No  
.4770  
0 














4.6 The Relation between  family history of thyroid problems and results of 
pregnant women 
As illustrated in Table 4.8 the mean levels of TSH, FT4 and FT3 showed 
increased in subject had history of thyroid problem in comparison to those who 
had not. These changes were not significant(t=0.678, p=0.499; 
t=1.516,p=0.133;t=.3790,p=0.705, respectively). 
Table:4.8 pregnant  whose family members were  suffering from thyroid disease. 
p-
value  t 
% 
Difference Std. 
Deviation Mean n 
  
Is there one in 
the family suffers 
from problems in 
the thyroid gland  
2.2  2.2  8  yes  
.4990  .6780  
13.6 
1.1 1.9 82 No 
TSH 
mIU/ml)(  
0.22  1.1  8 yes .1330  1.516  
14.5 
0.30 0.94 82  No  
FT4( ng/d) 
1.2  3.3  8  yes  .7050  .3790  
6.1  
1.4  3.1  82  No  
FT3(pg/ml) 
p> 0.05: not significant.  
p<0.05: significant. 
 
Table:4.9 illustrates the mean level of TSH, FT4 and FT3 in non pregnant for those 
had history of thyroid problem(1.5±0.67 mIU/ml,0.75±0.05 ng/d,2.4±0.70 pg/ml, 
respectively) had decreased mean levels compared to those who had not(2.0±0.95 
mIU/ml,0.89±0.19 ng/d, 2.8±0.68pg/m). These changes were not 
significant(p=0.073,p=0.087,p=0.600 respectively). 











Is there one in the family 
suffers from problems in 
the thyroid gland  
.670  1.5  6  Yes  
.0730  
33.3- 
.950  2.0  74 No  
TSH( mIU/ml) 
.050  .750  6  Yes .0870  18.6- .190 .890 74  No  FT4( ng/d)  
.700  2.4  6  Yes  
.6000  
16.6- 
.680 2.8 74  No  
FT3(pg/ml) 





4.7 The relation between genetic disease and thyroid hormone abnormalities 
The relation between genetic diseases and the thyroid hormone status in 
pregnant is summarized in Table 4.10. The mean level of the TSH was( 2.1±1.6  
mIU/ml) for those who had genetic disease in their family showed increased in 
comparison to those who had not(1.9±0.12 mIU/ml). These changes were not 
significant (t=0.668, p=0.506). FT4 and FT3 showed  non significant decreased 
between who had genetic disease in their family showed and those who had 
not(0.93±0.45 Vs0.97±0.26 ng/d, 2.8±1.6, 3.2±1.3 pg/ml, p=0.681, p=0.288, 
respectively)  
Table4:10.the relation between genetic disease and thyroid hormone 
abnormalities.  In pregnant  group. 
 
p-
value  t 
% 
Difference Std. Deviation Mean n 
Are there genetic 
diseases in the 
family  
1.6  2.1  16  Yes  
.5060  0.668  
9.5 
.120 1.9 74 No 
TSH 
(mIU/ml) 
0.45  0.93  16  Yes  .6810  .4130  4.3- 0.26 0.97  74 No FT4( ng/d) 
1.6  2.8  16  Yes  .2880  1.070 
14.2- 
1.3  3.2 74  No  
FT3(pg/ml) 
p> 0.05: not significant.  
p<0.05: significant. 
 
The status of thyroid function in relation to genetic disease in non pregnant is 
illustrated in Table 4.11. There was no significant differences in the hormones levels 
of TSH,FT4 and FT3 between who had genetic disease in their family showed and 
those who had not (p=0.078, p=0.739, p=0.928, respectively )  
 




Difference Std. Deviation  Mean  
  
n  
Are there genetic diseases 
in the family  
1.2  2.6  7  Yes  
.0780  
26.9 
0.89  1.9  73 No  TSH (mIU/ml) 
.170  .860  7  Yes  .7390  
2.3- 
0.19 .880 73  No  
FT4( ng/d)  
0.57  2.8  7  Yes  
.9280  
3.5 
.700  2.7  73 No  FT3(pg/ml) 





4.8 The Relation between thyroid problem and delivery. 
 
Table 4.12 provides the relation between thyroid function and natural of delivery . 
The independent t-test showed that mean levels of TSH, FT4 and FT3 decreased 
slightly in patients who had  normal delivery than patients who had abnormal 
delivery. .However, this difference was not significant(t=1.298, p=0.199; 
t=0.679,p=0.500; t=0.143,p=0.887, respectively). 
 
Table 4:12 The Relation between thyroid problem and delivery. In pregnant 
group. 
p-
value  t  
% 
Difference Std. Deviation Mean n 
Was the previous, 
delivery 
normal  
1.9  2.41 9 abnormal delivery .1990  1.298  
26.3- 
1.1  1.9  81 Normal delivery 
TSH 
mIU/ml)(  
0.38  1.1  9 abnormal delivery  0.500  .6790  
15.7- 
0.30  0.95 81 Normal delivery  
FT4( ng/d) 
1.1 3.2  9 abnormal delivery  0.887 0.143 
3.2- 
1.4  3.1  81 Normal delivery  
FT3(pg/ml) 
p> 0.05: not significant.  
p<0.05: significant. 
 
As indicated in Table 4.13. the mean level of TSH, FT4 and FT3 in patients who had  
abnormal delivery were higher than that patients who had  normal delivery 
(2.3±1.2Vs1.9±0.89 mIU/m, 0.94±0.19 Vs 0.87±0.18 ng/d, 3.1±0.46 Vs2.7±0.72 




















Difference Std. Deviation  Mean  
  
n  
was the previous, delivery 
normal  
1.2 2.3  9 
Abnorm
al-
delivery  .4020  
21- 
.890  1.9  71 Normal delivery  
TSH (mIU/ml) 
0.19 .940  9 
Abnorm
al-
delivery  0.283  
8.1- 
0.18  0.87 71  Normal delivery  
FT4( ng/d)  
0.46 3.1 9 
Abnorm
al-
delivery  0.069 
14.8- 




p> 0.05: not significant.  
p<0.05: significant. 
 
4.9 The Relation between thyroid problem and hypertension in pregnancy. 
The relation between hypertension and thyroid function in pregnancy is provided 
in Table 4.14. The independent t-test showed that   patients with hypertension had 
decreased mean levels of TSH, FT4 and FT3 compared to those who had 
not(1.7±1.3 mIU/ml, 0.83±0.44ng/d, 2.5±1.49pg/m Vs1.9±1.2 mIU/ml, 0.97±0.29 
ng/d, 3.2±1.4 pg/ml respectively ). These changes were not significant(t=0.380, 














Table 4:14 The Relation between thyroid problem and hypertension during 
pregnancy. 
p-
value  t  
% 
Difference Std. Deviation Mean n 
Hypertension 
during Pregnancy  
  
1.3  1.7  6  Yes 
.7050  .3800  
11.7- 
1.2  1.9  84 No 
TSH 
mIU/ml)(  
0.44  0.83  6  Yes  
0.291  1.063  
16.8- 
0.29  0.97 84 No FT4( ng/d) 
1.5  2.5  6  Yes  
0.218 1.241 
8 
1.4  2.3  84 No 
FT3(pg/ml) 
p> 0.05: not significant.  
p<0.05: significant. 
Hypertension in relation to thyroid hormones levels in non pregnant  is shown in 
Table 4.15. The mean of TSH, FT4 and FT3 levels showed a slightly difference in  
patients who had hypertension in comparison to those who had not. These changes 
were not significant(p=0.972, p=0.674, p=0.108, respectively) 
 





Deviation  Mean  n  
Hypertension 
Pregnancy  
.760 1.9  5  Yes  
.9270  
0 
.960  1.9  75 No  
TSH 
mIU/ml) 
.170  .840  5  Yes  
.670  
4.7- 
.190  0.88  75  No  
FT4(ng/d)  
.960  2.7  5  Yes  
.1080  
3.7- 
.670 2.8 75  No  FT3(pg/ml) 
p> 0.05: not significant.  
p<0.05: significant. 
 
4.10 The relation between thyroid hormone and age. 
In order to test the equality of means between the three age groups with respect to 
the three variables, we need to assess the normality of three variables among each 
group. The Kologorov-Simirnove test shows that most of them are not normally 




shown in Table 4.16 Thus the parametric test the One way ANOVA can't be used, 
Alternatively, we can use  Kruskal Wallis test as a non parametric test. 
 
 
Table 4.16 The Kologorov-Simirnove test for age group. 
Kolmogorov-Smirnova Shapiro-Wilk 
Age1 
Statistic df Sig. Statistic df Sig. 
TSH (mIU/ml) 0.183 45 0.001 0.916 45 0.003 
FT4( ng/d) 0.161 45 0.005 0.922 45 0.005 18-25 
FT3(pg/ml) 0.085 45 0.200 0.956 45 0.086 
TSH mIU/ml) 0.166 61 0.000 0.901 61 0.000 
FT4 (ng/d) 0.165 61 0.000 0.910 61 0.000 26-33 
FT3(pg/ml) 0.121 61 0.027 0.953 61 0.021 
TSH mIU/ml) 0.161 22 0.142 0.908 22 0.043 
FT4 (ng/d) 0.194 22 0.031 0.900 22 0.029 34-40 
FT3(pg/ml) 0.194 22 0.030 0.900 22 0.030 
 
Kruskal Wallis tests shows that there is no significant difference between the means 
of the three Variables with respect to the age groups were the p-values is greater than 
0.05 as shown in Table 4.17. 
 
Table 4.17 The relation between age and the thyroid hormone in pregnant 
 TSH mIU/ml) FT4( ng/d) FT3(pg/ml) 
Chi-Square 0.658 1.827 1.201 
p-value 0.720 0.401 0.549 
 
In non pregnant population where the mean of the age was 25.3 year when 
divided into group,  Kruskal Wallis Test is used.   There is a significant statistical 
difference between the groups of age for FT4 and FT3 As the p- value was 0.034 and 









Table 4.18 The relation between age and the thyroid hormone in non pregnant 
group. 
 TSH mIU/ml)  FT4(  ng/d) FT3(pg/ml) 
Chi-Square .1710  6.779 6.541 




4.11 The relation between thyroid function and gestational age 
As depicted from Table 4.19, there was no significant association between increasing 
in gestational age and TSH, FT4 and FT3(p=0.09, 0.575,0.685, respectively) 
 
Table 4.19 The relation between thyroid function and gestational age 
 
p-
value  t  
% 
Difference Std. Deviation Mean n   
0.96  1.8 54  9-13w  
0.09 1.712 
18.1 
1.5  2.2  36 1-8 w 
TSH 
mIU/ml)(  
0.27 0.97  54  9-13w  
0.575 0.562  
4.3- 
0.35  0.93 36 1-8 w FT4( ng/d) 
1.3  3.2  54  9-13w  
0.685 0.407 
-3.2 
1.5  3.1 36 1-8 w 
FT3(pg/ml) 
W :(gestational age  in weeks) 
p> 0.05: not significant.  
p<0.05: significant. 
 
4.12 The relation between the thyroid function and the number of pregnancies. 
For the control population the mean of number of pregnancies was 3.9 times .there is 
no correlation between the number of pregnancies and the TSH, FT4 and 









Table 4.20 The relation between the thyroid function and the number of 
pregnancies. 
  TSH 
mIU/ml)(  
FT4 (ng/d) FT3(pg/ml)  
Pearson Correlation -0.071- .0200  .1000  Number of 
pregnancies Sig. (2-tailed) .5370  .8640  .3910  
  
While the mean of number of pregnancy was 3.4 times  case population. there 
is no correlation between the number of pregnancies and the TSH, FT4 and 




Table 4.21 Number of pregnancies and thyroid hormone in cases. 
  TSH 
mIU/ml)( 
FT4( ng/d) FT3(pg/ml)  
Pearson Correlation .0880  .1360  .0220  Number of 












































Specific reference intervals for FT4, T4, T3 in addition to TSH during 
pregnancy may be particularly important for several reasons. First, it would be 
important to know what the FT4 levels are in the first trimester as they are higher than 
in other trimesters in a euthyroid pregnancy, and this is time when the fetus is wholly 
dependent on T4 from the mother. Accurate reference intervals for T4 and FT4 would 
then provide the ability to detect a deficiency at this critical time and provide a subtle 
indication of maternal hypothyroidism. Such hypothyroxinemia may be masked 
during the first trimester if that determination relied solely on an elevated TSH 
because of the stimulatory effect of high hCG levels on the thyroid gland. It is 
possible that high, sustained estrogen levels during this time are associated with 
transient lowering of serum TSH (120,121). Thus curtailing its rising above the 
normal non pregnant range. Second maintenance of normal maternal thyroid hormone 
levels is known to be a determinant of adequate fetal thyroid hormone levels early in 
pregnancy (122 and adequate mental and psychomotor development in infants (123) 
Better and easier measurements of T4 and FT4 during early pregnancy would 
contribute to better insights into the more appropriate method of detecting thyroid 
deficiency at this critical time for the fetus. Mild maternal hypothyroidism 
(subclinical hypothyroidism) has been implicated as the cause of neuro-psycho-
intellectual deficit in offspring (78,124). Accurate reference intervals in early 
pregnancy would make it possible to better define this condition. In cases of overt 
hypothyroidism the fetal consequences can be extreme (125). However, it appears that 
the maternal level and delivery of FT4 and not T3 to the fetus is critical for the 
neuropsychological development of the fetus (80). A deficiency may not be reflected 
by the degree of TSH elevation (126). It is imperative for normal intervals of thyroid 
hormones to be established for pregnant women especially it should be determined in 
early pregnancy and particularly T4 level which can be used to screen the fetus and 
pregnancy risk. 
 
This is the first study to investigate the status of thyroid function and to 




thyroid problems, and  genetic diseases on thyroid function. This could be useful in 
adopting strategies which may be applied for  pregnant women. 
 
5.1 General characteristics of the study population 
Data presented in this study dealt with 170 women's 80 non pregnant 
(controls) and 90 pregnant women's. The mean age of the cases in the present study 
was 24.8±5.6 years. This mean age was in the range to that reported in study 
measured blood levels of (TSH), (FT4) and (FT3)  for normal pregnant women 
randomly selected with mean age  of (28 ± 12) years(116). 
 
5.2 Hypothyroidism and Hyperthyroidism in pregnant women. 
Hypothyroidism was observed in 2.2%  of our population which is similar to that 
in European and American pregnant women where the prevalence was 2.2% and 
2.5% respectively.  (127-131). Our results are lower than those reported for 
pregnant women in Tunisia which was 3.2%. However, iodine deficiency could 
contribute to the development of hypothyroidism in some of these women in our 
study. While the Gaza city is considered as marginally iodine sufficient, the 
increase of iodine requirement during pregnancy may cause substantial iodine 
deficit that induces thyroid insufficiency, which  may be due to the use of non-
iodized salt in Gaza city. The higher prevalence of hypothyroidism in advanced 
gestation suggests that iodine deficiency is probably a key contributor of 
hypothyroidism in our pregnant women. Hypothyroidism might be caused by 
defect in iodine metabolism. However, following iodine metabolism in the study 
group was beyond the objectives of this research.  Also the economic situation in 
the country does not allow the presence of system with prefect food for pregnant 
women. This  system should provide protection to pregnant women of any 
malnutrition during pregnancy. Other reasons for higher prevalence of 
hypothyroidism in our study may be due to the remnants of war (like as 
perchlorate contaminates, Perchlorate acts by inhibiting the thyroid's ability to 
take up the nutrient iodide, which is a key building block for thyroid hormones. If 
the thyroid gland does not have enough iodide for a sufficient period of time, the 
body's thyroid hormone levels will eventually drop.) in the recent contamination 




Another cause might be due to misuse of Pesticides by farmers, this lead to 
contamination of vegetables and fruits which ultimately affects human 
health(132).  
Hyperthyroidism was observed in 1.0 % of our pregnant women , it  was more 
or less similar than that reported in Tunisia ( 1.3%). Because diagnosis was based 
solely on TSH value, the etiology of hyperthyroidism was uncertain. Another cause of 
hyperthyroidism may be due to ignorance of  women who do not seek medical advise. 
 
 
5.3 Thyroid parameters in pregnant and  non pregnant women. 
This study showed a significant difference between pregnant and non-pregnant 
women. in relation to FT4 and FT3 means. However, The mean TSH level of pregnant 
women was lower than that of non-pregnant women, but did not show a significant 
difference between pregnant and non-pregnant women. Similar studied have revealed the 
mean TSH level in the study was closely similar to what we found (116,133). 
 
Panesar and his colleagues found that the FT3 decreased during pregnancy, 
while the FT4 initially increased, peaking between 9-13 weeks(134) In our study, 
changes in the serum levels of FT4 in pregnant women were closely similar to the previous 
study.  We also found that the highest level of FT3 was during the first trimester, Similar to 
that found in the study in china (116). It seems that the target groups of different 
researches  share many characteristics like living conditions and social habits. 
 On the other hand, the present results were not concordant with some other 
studies in this field. Kurioka and his colleagues reported significantly reduced levels of 
free T3 and free T4(135). Also, Kumar reported that TSH values were increased 
steadily with each trimester(110). 
 
 Our results are similar to those reported by Marwaha with the exception of the 
free T4 values(136).  However, the difference between our study and theirs may be 








5.4 The Relation between  thyroid hormones and pregnancy 
Data revealed that there is no significant difference  between those who had 
abnormal thyroid hormones and those who had normal hormones levels in cases 
group as in control group. the group who had abnormal thyroid function had 
elevated TSH but normal FT4This means that  they had subclinical 
hypothyroidism (59).  also known as mild hypothyroidism that has not 
progressed.(137) 
5.5The Relation between  family history of thyroid problems and results of 
pregnant women and non pregnant women. 
Data revealed that there is no significant difference in  subjects who  had history 
of thyroid problem in their family and subjects who did not have family thyroid 
problem. In our society the habits does not allow the person to declare about disease  
in his family, even those who declares of having family history of thyroid problems 
may not be first –class kinship to pregnant women. The number of cases who had 
family history of thyroid problems are small compared to the total sample size. 
Vaidya have reported that targeted thyroid function testing of only pregnant women at 
high risk for thyroid disease (e.g. family history of thyroid disease) would miss about 
one-third of women with overt and subclinical thyroid disease(138). 
5.6 The relation between genetic disease and thyroid hormone abnormalities 
Data revealed that there is no significant difference in  subjects who  had 
genetic diseases and  those who do not have. This applies to both case and control 
groups. It seems that women are not educated enough to understand the nature of 
genetic disease 
5.7 The Relation between thyroid problem and hypertension in pregnancy. 
Our results do not show any relationship between thyroid function and hypertension, 
this may be due to adequate follow up of each subject was not done. During early 
pregnancy, blood pressure levels normally decrease, but during the second and third 
trimesters, they begin to steadily rise. If blood pressure was high in pregnancy, known 
as chronic hypertension; if first develop hypertension only after the first twenty weeks 
of pregnancy, its gestational hypertension.  develop gestational hypertension if,  




• Experiencing a first pregnancy 
• Have a kidney disease 
• Have diabetes (chronic or gestational) 
• Are not eating well 
 
Women with chronic hypertension tend to have a family history of hypertension. 
Chronic hypertension is more common in women over thirty-five and is aggravated 
by smoking, obesity, or kidney problems.(24) 
5.8 The relation between thyroid hormone and age. 
  Results of the control group showed significant relationship between age and 
both FT3 and FT4. 
                                                                                                                                                                                                                                                                                                                                                                               
This may be due to fact that the mean age of the control( 29.32 years) which is more 
than the mean age of cases( 24.89 years). this is in agreement with other studies, in 
multivariate models, TSH increased by 0.03 mIU/L for every additional year of 
maternal age (P = .03) (139). Also reported that  TSH showed significant differences 
(P < .005) according to the age of the mother(140). 
 
5.9 The relation between thyroid function and gestational age. 
TSH level during the first few weeks was higher than the subsequent weeks. It 
seems that TSH levels are affected by the level of HCG.  High level of HCG are 
accompanied by lower levels of TSH and vice versa(4,99). However, we did not 



























CONCLUSIONS AND RECOMMENDATIONS 
6.1 Conclusions 
1. Hypothyroidism was observed in 2.38 % of our population, 2.2% in pregnant 
women and (2.5%) in non pregnant women.  While hyperthyroidism was observed in 
1.0 % of our pregnant women.   
2. The  study showed a significant difference between pregnant and non-pregnant 
women in relation to FT4 and FT3 level. 
3. The mean TSH levels of pregnant women was lower than the mean level of non 
pregnant. However these results were not statistically significant. 
4. There was no significant difference  between those who had abnormal thyroid 
hormones and those who had normal hormones levels in cases as well as in control 
group.  
5. There was no significant difference between those who had history of thyroid 
problem in their family and those who did not have history of thyroid problem in their 
family in cases as well as in control group. 
6. There was no significant difference  between  those who had genetic disease in 
their family and those who did not in both  cases and in control. 
7. There is no significant difference between those who had past  abnormal delivery 
and those who had past normal delivery. 
8. There was no significant difference between those who had hypertension during 
pregnancy and those who did not have hypertension . 
9. There was significant relationship between age and both FT3 and FT4 in the 
control group. 







1- Thyroid function testing TSH and FT4 studies prior to conception or in early 
pregnancy is recommended. 
2 -Pregnant women in the following categories should have thyroid function assessed 
either at diagnosis or at antenatal booking, or even before conception if feasible type-
1 diabetes, previous history of thyroid disease, current thyroid disease, family history 
of thyroid disease, goiter, symptoms of hypothyroidism 
3- Assessment  thyroid peroxidase (TPO) antibodies. 
4- Assessment of HCG level in the first trimester of pregnancy. 
5-More research concerning thyroid gland  should be performed to include 2nd and 3rd 
trimester with larger sample size.  
 6-It is recommended to launch a program aiming at determination of normal levels 
of thyroid hormones during the three phases of pregnancy.  
7- The relationship between thyroid hormones and other hormones during pregnancy 
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